Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 70Observational 3

Sponsor

Cancer Type

Lymphoid 2Genitourinary 2

Conditions

Lymphoma, Mantle-Cell 2Carcinoma, Renal Cell 2Carcinoma 1

Interventions

Sunitinib 16exemestane 11Afatinib 11palbociclib 10Rituximab 10Bevacizumab 10Erlotinib Hydrochloride 9Leuprolide 8Radiotherapy 7Drug Therapy 7Axitinib 7avelumab 6Letrozole 6Capecitabine 6Blood Specimen Collection 6enzalutamide 5Trastuzumab 5Surveys and Questionnaires 5Standard of Care 5Docetaxel 5Aromatase Inhibitors 5lorlatinib 4Specimen Handling 4Radiation 4Mammography 4Crizotinib 4Anastrozole 4Abiraterone Acetate 4temsirolimus 3talazoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Has results × temsirolimus × Clear all
NCT01210482 2024-09-25

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Pfizer

Completed
1,050 enrolled 9 charts
Genitourinary

Carcinoma, Renal Cell

NCT00700258 2024-09-23

STAR-TOR

Pfizer

Completed
1,520 enrolled 24 charts
Lymphoid

Carcinoma, Lymphoma, Mantle-Cell

NCT01367457 2016-04-27

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Pfizer

Completed
243 enrolled 12 charts
GenitourinaryLymphoid

Carcinoma, Renal Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡